David William Dodick

David William Dodick's AcademicInfluence.com Rankings

Philosophy

#4433

World Rank

#6942

Historical Rank

Logic

#1884

World Rank

#2748

Historical Rank

philosophy Degrees

Download Badge

Philosophy

David William Dodick's Degrees

Doctorate Medicine University of Manitoba

Why Is David William Dodick Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David William Dodick's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Narrative Review: Reversible Cerebral Vasoconstriction Syndromes (2007) (814)
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease (1999) (794)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program (2010) (744)
New Appendix Criteria Open for a Broader Concept of Chronic Migraine (2006) (711)
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults (2012) (546)
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial (2008) (489)
The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—-Revision of Criteria for 8.2 Medication-Overuse Headache (2005) (485)
A self-administered screener for migraine in primary care (2003) (462)
Fremanezumab for the Preventive Treatment of Chronic Migraine (2017) (460)
Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial (2007) (420)
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study (2011) (381)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine (2018) (367)
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial (2018) (366)
Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial (2010) (363)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial (2018) (330)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study (2014) (293)
Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of Migraine (2004) (292)
Adherence to oral migraine-preventive medications among patients with chronic migraine (2014) (291)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial (2014) (282)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial (2016) (278)
Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Long-term results from a randomized, multicenter, double-blinded, controlled study (2012) (241)
Clinical, Anatomical, and Physiologic Relationship Between Sleep and Headache (2003) (238)
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine (2011) (238)
A Phase‐by‐Phase Review of Migraine Pathophysiology (2018) (231)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study (2015) (230)
Central Sensitization Theory of Migraine: Clinical Implications (2006) (229)
Guidelines for the diagnosis and management of migraine in clinical practice (1997) (226)
Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study (2005) (225)
Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study (2012) (222)
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis (2016) (219)
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial (2014) (212)
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine (2016) (203)
Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well‐Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program (2010) (200)
Towards a Definition of Intractable Headache for Use in Clinical Practice and Trials (2006) (196)
Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults (2018) (196)
Functional MRI of migraine (2015) (186)
Ubrogepant for the Treatment of Migraine. (2019) (185)
The Sinus, Allergy and Migraine Study (SAMS) (2007) (182)
Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches – A Narrative Review (2013) (180)
Triptan‐induced latent sensitization: A possible basis for medication overuse headache (2009) (174)
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline (2013) (166)
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society (2012) (165)
Deep Brain Stimulation for Intractable Chronic Cluster Headache: Proposals for Patient Selection (2004) (165)
Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study (2016) (161)
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. (2019) (154)
Advanced neuroimaging of migraine (2009) (140)
United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data. (2016) (140)
Trial of Galcanezumab in Prevention of Episodic Cluster Headache. (2019) (139)
Chronic migraine—classification, characteristics and treatment (2012) (134)
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine (2011) (131)
Treatment of medication-overuse headache: A systematic review (2016) (130)
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition (2019) (127)
The young brain and concussion: Imaging as a biomarker for diagnosis and prognosis (2012) (127)
Chronic Daily Headache (2006) (126)
Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study (2015) (125)
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED] (2012) (122)
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial (2017) (122)
Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. (2016) (122)
Migraine (2018) (121)
Diagnostic Criteria for Headache Due to Spontaneous Intracranial Hypotension: A Perspective (2011) (120)
Stroke Team Remote Evaluation Using a Digital Observation Camera in Arizona: The Initial Mayo Clinic Experience Trial (2010) (120)
Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. (2009) (119)
Stroke telemedicine. (2009) (118)
Tau Positron‐Emission Tomography in Former National Football League Players (2019) (118)
Enhanced pain-induced activity of pain-processing regions in a case-control study of episodic migraine (2014) (117)
Topiramate Treatment of Chronic Migraine: A Randomized, Placebo‐Controlled Trial of Quality of Life and Other Efficacy Measures (2009) (115)
Outcome of trigeminal nerve section in the treatment of chronic cluster headache (2003) (114)
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT (2014) (114)
Activation of TRPA1 on dural afferents: A potential mechanism of headache pain (2012) (110)
Triptan Nonresponder Studies: Implications for Clinical Practice (2005) (108)
Cardiovascular Tolerability and Safety of Triptans: A Review of Clinical Data (2004) (108)
CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications (2019) (106)
Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study (2020) (102)
Pathophysiology, prevention, and treatment of medication overuse headache (2019) (98)
Acute treatment and prevention of menstrually related migraine headache (2008) (97)
Refining the Clinical Spectrum of Chronic Paroxysmal Hemicrania: A Review of 74 Patients (2002) (96)
Polysomnography in Hypnic Headache Syndrome (2000) (96)
A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study) (2018) (96)
Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. (2010) (96)
Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings (2015) (95)
Post-traumatic headache: epidemiology and pathophysiological insights (2019) (95)
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis (2001) (95)
Sinus headache: a neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatment. (2005) (94)
MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine (2011) (90)
Clinical practice. Chronic daily headache. (2006) (86)
Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences (2018) (86)
Responsiveness of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing to hypothalamic deep brain stimulation. (2009) (85)
Evidence‐Based Understanding of Medication‐Overuse Headache: Clinical Implications (2006) (85)
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial (2021) (85)
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis (2001) (84)
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial (2019) (84)
Topiramate in Cluster Headache Prophylaxis: an Open Trial (2003) (84)
Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. (1998) (84)
Capturing the aversive state of cephalic pain preclinically (2013) (83)
TEV-48125 for the preventive treatment of chronic migraine (2016) (83)
Smartphone Teleradiology Application Is Successfully Incorporated Into a Telestroke Network Environment (2012) (83)
Caffeine for the Prevention and Treatment of Postdural Puncture Headache: Debunking the Myth (2007) (82)
Absent pachymeningeal gadolinium enhancement on cranial MRI despite symptomatic CSF leak (1999) (82)
Treatment and management of cluster headache (2001) (80)
Pharmacological Approaches to Managing Migraine and Associated Comorbidities—Clinical Considerations for Monotherapy Versus Polytherapy (2007) (79)
Hypnic Headache: Another Indomethacin‐Responsive Headache Syndrome? (2000) (78)
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine (2019) (77)
Transcranial Magnetic Stimulation for Migraine: A Safety Review (2010) (77)
Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine (2012) (75)
Occipital Nerve Stimulation for Headache: Mechanisms and Efficacy (2008) (74)
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial (2020) (74)
Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial (2019) (73)
Patent Foramen Ovale and Migraine—Bringing Closure to the Subject (2006) (72)
Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study (2018) (71)
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment (2020) (71)
Botulinum Neurotoxin for the Treatment of Migraine and Other Primary Headache Disorders: From Bench to Bedside (2003) (70)
Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults (2020) (69)
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. (2004) (68)
Targeting TRP Channels For Novel Migraine Therapeutics (2014) (68)
Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain (2018) (66)
The role of digital subtraction myelography in the diagnosis and localization of spontaneous spinal CSF leaks. (2012) (65)
Patent foramen ovale and migraine (2007) (65)
Pearls: headache. (2010) (65)
Pituitary apoplexy presenting as a thunderclap headache (1998) (64)
The Impact of Topiramate on Health‐Related Quality of Life Indicators in Chronic Migraine (2007) (63)
An Otolaryngology, Neurology, Allergy, and Primary Care Consensus on Diagnosis and Treatment of Sinus Headache (2006) (63)
Migraine and Cerebral White Matter Lesions: When to Suspect Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) (2005) (63)
Migraine: integrated approaches to clinical management and emerging treatments (2021) (62)
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021) (62)
Patent foramen ovale, stroke, and cardiovascular disease in migraine (2007) (62)
Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache (2014) (60)
Vascular malformations and intractable epilepsy: outcome after surgical treatment. (1994) (60)
Zolmitriptan nasal spray in the acute treatment of cluster headache (2007) (60)
Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention (2017) (59)
Vascular safety of erenumab for migraine prevention (2019) (59)
Indomethacin-responsive headache syndromes (2004) (59)
Duration of Migraine Is a Predictor for Response to Botulinum Toxin Type A (2005) (58)
SUNCT Responsive to Gabapentin (2002) (58)
Occipital nerve stimulation: technical and surgical aspects of implantation. (2011) (57)
Migraine and risk of stroke (2020) (57)
Long‐Term Outcome in Occipital Nerve Stimulation Patients With Medically Intractable Primary Headache Disorders (2013) (55)
Speed of Onset, Efficacy and Tolerability of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine (2005) (55)
Crescendo Transient Aura Attacks: A Transient Ischemic Attack Mimic Caused by Focal Subarachnoid Hemorrhage (2009) (55)
Greater occipital nerve stimulation via the Bion microstimulator: implantation technique and stimulation parameters. Clinical trial: NCT00205894. (2009) (55)
Occipital nerve stimulation with the Bion® microstimulator for the treatment of medically refractory chronic cluster headache. (2011) (54)
Diagnosis and treatment of migraine. (2002) (54)
Thunderclap Headache Associated with Reversible Vasospasm and Posterior Leukoencephalopathy Syndrome (2003) (53)
Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. (1997) (53)
Pathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies (2011) (52)
How Does Almotriptan Compare With Other Triptans? A Review of Data From Placebo‐Controlled Clinical Trials (2002) (52)
CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice (2019) (51)
Oral Almotriptan in the Treatment of Migraine: Safety and Tolerability (2001) (51)
Analgesic Overuse Is Not A Cause of Chronic Daily Headache (2002) (51)
Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents (2017) (50)
Migraine and white matter hyperintensities (2005) (50)
Migraine Genetics: Part II (2013) (49)
Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine). (2009) (49)
Reversible Segmental Cerebral Vasoconstriction (Call-Fleming Syndrome): the Role of Calcium Antagonists (2003) (49)
Migraine-related disability (2001) (49)
Late-life migraine accompaniments: A narrative review (2015) (48)
Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study (2019) (47)
Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. (2015) (46)
CT Interpretation in a Telestroke Network: Agreement Among a Spoke Radiologist, Hub Vascular Neurologist, and Hub Neuroradiologist (2012) (46)
Defining the Pharmacologically Intractable Headache for Clinical Trials and Clinical Practice (2010) (46)
Sensitivity of MRI of the spine compared with CT myelography in orthostatic headache with CSF leak (2013) (45)
Spontaneous CSF leak treated with percutaneous CT-guided fibrin glue (2005) (45)
Identifying the Factors Underlying Discontinuation of Triptans (2014) (45)
Evaluation of cutaneous allodynia following induction of cortical spreading depression in freely moving rats (2011) (44)
Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study (2011) (44)
Examining the Essence of Migraine—Is it the Blood Vessel or the Brain? A Debate (2008) (44)
Clinical clues and clinical rules: Primary vs secondary headache (2003) (44)
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults (2012) (44)
Migraine‐Associated Seizure: A Case of Reversible MRI Abnormalities and Persistent Nondominant Hemisphere Syndrome (2000) (43)
Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial (2019) (43)
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine (2020) (42)
Antimigraine Efficacy of Telcagepant Based on Patient's Historical Triptan Response (2011) (42)
Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study (2019) (42)
Thunderclap Headache (2002) (41)
Epidemiology, Risk Factors, and Treatment of Chronic Migraine: A Focus on Topiramate (2008) (41)
A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial (2017) (41)
Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines (2017) (41)
Proposals for New Standardized General Diagnostic Criteria for the Secondary Headaches (2009) (40)
Proposed new diagnostic criteria for chronic migraine (2020) (40)
DHE in the Pharmacotherapy of Migraine: Potential for a Larger Role (2006) (40)
Migraine with Isolated Facial Pain: A Diagnostic Challenge (2007) (40)
Migraine headache is present in the aura phase (2012) (40)
Atypical age-related cortical thinning in episodic migraine (2014) (39)
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes (2017) (39)
Why migraines strike. (2008) (38)
Erratum: The international classification of headache disorders, 2nd edition (ICHD-II) - Revision of criteria for 8.2 Medication-overuse headache (Cephalalgia (2005) 25, (460-465)) (2006) (38)
Headache After Resection of Acoustic Neuroma (1999) (38)
Corrigendum: Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study (Cephalalgia (2012) 32, 16 (1165-1179) DOI: 10.1177/0333102412462642) (2014) (38)
Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM) (2015) (37)
Three‐dimensional measurement of essential tremor (1999) (37)
Migraine: What Imaging Reveals (2016) (37)
Painful ophthalmoplegia: Overview with a focus on tolosa-hunt syndrome (2004) (37)
Chronic Paroxysmal Hemicrania Presenting as Otalgia With a Sensation of External Acoustic Meatus Obstruction: Two Cases and a Pathophysiologic Hypothesis (1998) (37)
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache (2020) (37)
Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is not a cause of chronic daily headache. (2002) (36)
Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. (2015) (36)
Fremanezumab for preventive treatment of migraine (2018) (36)
Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine (2007) (35)
Diagnosis and treatment of cluster headache. (2006) (34)
Thunderclap Stroke: Embolic Cerebellar Infarcts Presenting as Thunderclap Headache (2006) (34)
The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females (2020) (34)
Operational Diagnostic Criteria for Chronic Migraine: Expert Opinion (2014) (34)
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study (2020) (34)
Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II (2020) (33)
Hemicrania Continua: An Indomethacin‐Responsive Case With an Underlying Malignant Etiology (2002) (33)
Zolmitriptan Nasal Spray in the Acute Treatment of Cluster Headache: A Meta‐Analysis of Two Studies (2009) (33)
Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective (2018) (33)
How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians (2005) (33)
Antiepileptic Drugs for the Treatment of Chronic and Episodic Cluster Headache: A Review (2007) (33)
Evaluation and management of asymptomatic carotid artery stenosis. (2004) (33)
Comprehensive management of patients presenting to the otolaryngologist for Sinus pressure, pain, or headache (2015) (32)
Headache associated with sexual activity: Demography, clinical features, and comorbidity. Commentary (2003) (32)
Acute Treatment of Migraine with Zolmitriptan 5mg Orally Disintegrating Tablet (2004) (31)
Treatment of Chronic Migraine (2011) (31)
Headache as a symptom of ominous disease. What are the warning signals? (1997) (31)
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies (2019) (31)
Cluster headache: diagnosis and treatment. (2010) (30)
Percutaneous occipital stimulator lead tip erosion: report of 2 cases. (2008) (30)
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace (2021) (30)
The use of multiattribute decision models in evaluating triptan treatment options in migraine (2005) (30)
Management of Chronic Daily Headache: Challenges in Clinical Practice (2005) (30)
Hemicrania Continua Secondary to an Ipsilateral Brainstem Lesion (2007) (29)
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing (2020) (29)
Migraine prevention (2007) (29)
Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database (2016) (28)
Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine (2017) (28)
Pathophysiology and management of transformed migraine and medication overuse headache. (2006) (28)
Predictors of Migraine Headache Recurrence: A Pooled Analysis From the Eletriptan Database (2007) (28)
Stimulation Ranges, Usage Ranges, and Paresthesia Mapping During Occipital Nerve Stimulation (2008) (28)
Extratrigeminal Episodic Paroxysmal Hemicrania. Further Clinical Evidence of Functionally Relevant Brain Stem Connections (1998) (27)
Thunderclap headache: An approach to a neurologic emergency (2007) (27)
Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine (2016) (27)
Familial trigeminal neuralgia and contralateral hemifacial spasm (1999) (27)
Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines (S20.001) (2018) (27)
Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study (2019) (27)
Removing Barriers to Appropriate Migraine Treatment: Formulary Limitations and Triptan Package Size (2005) (26)
Teleconcussion: an innovative approach to screening, diagnosis, and management of mild traumatic brain injury. (2012) (26)
Simvastatin for Migraine Prevention (2007) (26)
Hemicrania Continua: Diagnostic Criteria and Nosologic Status (2001) (26)
The face of chronic migraine: epidemiology, demographics, and treatment strategies. (2009) (25)
RAPID REGULATION OF PAIN BY ESTROGENS SYNTHESIZED IN SPINAL DORSAL HORN NEURONS (2007) (25)
Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache (2018) (25)
Acute disseminated encephalomyelitis after accidental injection of a hog vaccine: successful treatment with plasmapheresis. (1998) (25)
Medication Overuse Headache in Patients with Primary Headache Disorders (2005) (25)
Chronic Daily Headache An Evidence-Based and Systematic Approach to a Challenging Problem (2011) (24)
Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data (2019) (24)
Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study (S17.001) (2019) (24)
The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort (2019) (24)
Concussion in Ice Hockey: Current Gaps and Future Directions in an Objective Diagnosis (2017) (24)
Spontaneous intracranial hypotension (2007) (24)
Clomiphene Citrate as a New Treatment for SUNCT: Hormonal Manipulation for Hypothalamic‐Influenced Trigeminal Autonomic Cephalalgias (2005) (23)
Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials (2019) (23)
King-Devick Test Identifies Symptomatic Concussion in Real-time and Asymptomatic Concussion Over Time. (S11.003) (2014) (23)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 for the Prevention of Episodic Migraine (2015) (23)
Paroxysmal sleep as a presenting symptom of bilateral paramedian thalamic infarctions. (2003) (23)
Sustained-release niacin for prevention of migraine headache. (2003) (23)
Diagnosing Headache : Clinical Clues and Clinical Rules (2003) (22)
Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). (2004) (22)
Almotriptan Increases Sustained Pain‐Free Outcomes in Acute Migraine: Results From Three Controlled Clinical Trials (2002) (22)
Sub-classifying patients with mild traumatic brain injury: A clustering approach based on baseline clinical characteristics and 90-day and 180-day outcomes (2018) (22)
The Effect of In-School Saccadic Training on Reading Fluency and Comprehension in First and Second Grade Students (2017) (22)
Thunderclap headache (2002) (22)
Acute and prophylactic management of migraine. (2001) (22)
Proceedings From the Ice Hockey Summit on Concussion: A Call to Action (2011) (21)
Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis (2019) (21)
Efficacy of (S)-lacosamide in preclinical models of cephalic pain (2016) (21)
Systematic review of outcomes and endpoints in preventive migraine clinical trials (2021) (21)
Chronic daily headache: a rational approach to a challenging problem. (2003) (21)
Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults (Cephalalgia (2008) 28, (484-495)) (2008) (20)
Risk of Development of Medication Overuse Headache With Nonsteroidal Anti-inflammatory Drug Therapy for Migraine: A Critically Appraised Topic (2011) (20)
Migraine prophylaxis with botulinum toxin A is associated with perception of headache. (2009) (20)
Is There a Preferred Triptan? (2002) (20)
Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency (2021) (20)
Safety and effi cacy of ALD 403 , an antibody to calcitonin gene-related peptide , for the prevention of frequent episodic migraine : a randomised , double-blind , placebo-controlled , exploratory phase 2 trial (2014) (20)
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension (2020) (20)
Medication‐Induced (Analgesic Rebound) Headache: Historical Aspects and Initial Descriptions of the North American Experience (2001) (20)
Patient experience of telemedicine for headache care during the COVID‐19 pandemic: An American Migraine Foundation survey study (2021) (20)
Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine Tracker (2018) (19)
King-Devick Test identifies real-time concussion and asymptomatic concussion in youth athletes (2017) (19)
Migraine in special populations (2003) (19)
Long-term safety, tolerability, and efficacy of fremanezumab in migraine (2020) (19)
Revised 2004 International Classification of Headache Disorders: New Headache Types (2004) (19)
Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project (2004) (18)
Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache (2020) (18)
Systematic review of outcomes and endpoints in acute migraine clinical trials (2021) (18)
Reversible Cerebral Vasoconstriction Syndrome (2013) (18)
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data (2021) (18)
Migraine-related disability: Impact and implications for sufferers’ lives and clinical issues (2001) (18)
Sarcomas of calvarial bones (1994) (18)
Progressive cervical myelopathy secondary to chronic ventriculoperitoneal CSF overshunting (2005) (18)
Migraine With Aura Is a Risk Factor for Cardiovascular and Cerebrovascular Disease: A Critically Appraised Topic (2007) (17)
Oral Sumatriptan for the Acute Treatment of Probable Migraine: First Randomized, Controlled Study (2006) (17)
Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists (2019) (17)
Thunderclap headache (2006) (17)
The Headaches That Awaken Us (2006) (17)
A review of the clinical efficacy and tolerability of almotriptan in acute migraine (2003) (17)
The Young Woman With Postpartum “Thunderclap” Headache (2005) (17)
Headache characteristics and burden from chronic migraine with medication overuse headache: Cross‐sectional observations from the Medication Overuse Treatment Strategy trial (2021) (17)
From Hemicrania Lunaris to Hemicrania Continua: An Overview of the Revised International Classification of Headache Disorders (2004) (17)
Effect of Migraine on Pregnancy Planning: Insights From the American Registry for Migraine Research. (2020) (16)
Treatment preferences and the selection of acute migraine medications: results from a population-based survey (2004) (16)
Occipital nerve stimulation for chronic cluster headache (2003) (16)
Tearing without pain after trigeminal root section for cluster headache (2005) (16)
Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project (2021) (16)
Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan* (2011) (15)
Procedural Headache Medicine in Neurology Residency Training: A Survey of US Program Directors (2016) (15)
Identifying migraine in primary care settings. (2005) (15)
Fremanezumab for preventive treatment of migraine Functional status on headache-free days (15)
Vancouver Declaration on Global Headache Patient Advocacy 2018 (2018) (15)
Proceedings from the Ice Hockey Summit on Concussion: A Call to Action (2011) (15)
Migraine with and without aura and risk for cardiovascular disease (2008) (15)
Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data (2020) (15)
Patient Perceptions and Treatment Preferences in Migraine Management (2002) (15)
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications (2020) (15)
Familial Hemiplegic Migraine: Permanent Attack‐Related Neurologic Deficits (2007) (14)
Sporadic Hemiplegic Migraine With Permanent Neurological Deficits (2014) (14)
A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain (2020) (14)
The Effect of Prophylactic Medications on TMS for Migraine Aura (2010) (14)
Views and Perspectives Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT 1B/1D Agonists) in the Acute Treatment of Migraine (2004) (14)
Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome (2021) (13)
An Emerging Role for Prolactin in Female-Selective Pain (2020) (13)
Sensory Hypersensitivity Symptoms in Migraine With vs Without Aura: Results From the American Registry for Migraine Research (2020) (13)
Migraine Genetics – A Review: Part I (2013) (13)
Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache (2020) (13)
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura (2021) (13)
Impact of Depression and Anxiety Symptoms on Patient‐Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR) (2020) (13)
Proceedings from the Ice Hockey Summit III: Action on Concussion. (2019) (13)
CGRP antagonists in the acute treatment of migraine (2004) (13)
Measurement and implications of the distance between the sphenopalatine ganglion and nasal mucosa: a neuroimaging study (2018) (12)
Headache attributed to non-vascular intracranial disorder. (2010) (12)
Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: Results From a Single-Attack Phase 3 Study, ACHIEVE II (S38.008) (2019) (12)
Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials (2021) (12)
Advances in migraine management: implications for managed care organizations. (2004) (12)
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis (2021) (12)
Acute treatment patterns in patients with migraine newly initiating a triptan (2020) (12)
Trigeminal Autonomic Cephalalgias: Current and Future Treatments (2007) (12)
Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine (2021) (11)
Posttraumatic headache. (2012) (11)
Intractable SUNCT Cured After Resection of a Pituitary Microadenoma (2006) (11)
ACGME competencies in neurology (2009) (11)
Real‐world efficacy, tolerability, and safety of ubrogepant (2021) (11)
Triptan Use and Discontinuation in a Representative Sample of Persons With Migraine: Results From Migraine in America Symptoms and Treatment (MAST) Study (P4.10-019) (2019) (11)
[123I]-IMP single-photon emission computed tomography imaging in visual snow syndrome: A case series (2020) (10)
Occipital Nerve Stimulator Placement Under General Anesthesia: Initial Experience With 5 Cases and Review of the Literature (2010) (10)
Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP peptide antibody in the prevention of chronic migraine. (S52.003) (2017) (10)
Orthostatic Headache Syndrome with Csf Leak Secondary To Bony Pathology of the Cervical Spine (2002) (10)
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response (2020) (10)
Taking the headache out of migraine. (2015) (10)
White matter hyperintensities in migraine: reason for optimism. (2012) (10)
Milestone-compatible neurology resident assessments (2015) (10)
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study (2021) (10)
Occipital Nerve Stimulation for Migraine: Update from Recent Multicenter Trials. (2015) (10)
Headache research in 2015: progress in migraine treatment (2016) (10)
Ice Hockey Summit II: zero tolerance for head hits and fighting. (2015) (9)
Tourette's syndrome. Current approaches to recognition and management. (1992) (9)
Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult‐to‐Treat Migraine Headaches (2019) (9)
Red ear syndrome (2007) (9)
Cluster and chronic daily headache (2003) (9)
Acute Migraine: Which Triptan? (2004) (9)
Tonabersat for migraine prevention: new life or last gasp? (2009) (9)
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine (2020) (9)
Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study (2019) (9)
Patient-Centered Treatment of Chronic Migraine With Medication Overuse (2022) (9)
CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache (2021) (9)
Ice Hockey Summit II: Zero Tolerance for Head Hits and Fighting (2015) (9)
Reflections and Speculations on Refractory Migraine: Why Do Some Patients Fail to Improve With Currently Available Therapies? (2008) (9)
Patient-focused migraine management: establishing needs. (2003) (8)
Giant cell arteritis (2006) (8)
Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. (2004) (8)
Proceedings from the ice hockey summit on concussion: a call to action. (2011) (8)
Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post‐Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial (2018) (8)
A Multicenter, Prospective, Single Arm, Open Label, Post-Market, Observational Study to evaluate the use of sTMS in reduction of Migraine Headache (ESPOUSE Study) (S52.004) (2017) (8)
Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study (2020) (8)
A Cross-Study Analysis for Reproducible Sub-classification of Traumatic Brain Injury (2018) (8)
Impact of abuse on migraine‐related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research (2021) (8)
EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study (2014) (7)
Imploding and Exploding Migraine Headaches: Comparison of Methods to Diagnose Pain Directionality (2014) (7)
Googling migraine: A study of Google as an information resource of migraine management (2020) (7)
Prevention of Episodic Migraine with AMG 334, a Human Anti-Calcitonin Gene-Related Peptide Receptor Monoclonal Antibody: Phase 2 Study Results and 52-Week Analysis of Open-Label Extension (S26.002) (2016) (7)
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia (2021) (7)
Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+ Year Results of a 5-year, Open-label Treatment Period (1203) (2020) (7)
Refractory headaches treated with bilateral occipital and temporal region stimulation (2014) (7)
Depicting the pterygopalatine ganglion on 3 Tesla magnetic resonance images (2018) (7)
A prolactin-dependent sexually dimorphic mechanism of migraine chronification (2021) (7)
Vancouver Declaration II on Global Headache Patient Advocacy 2019 (2018) (6)
Question & answer session. (2009) (6)
The migraine landscape on YouTube: A review of YouTube as a source of information on migraine (2020) (6)
Autonomic Nervous System Dysfunction in Concussion (IN5-2.005) (2013) (6)
Brainstem Dysfunction in Chronic Migraine as Evidenced by Neurophysiological and Positron Emission Tomography (PET) Studies—An Editorial Comment (2007) (6)
Critical Decisions in Headache Management (1998) (6)
Treatment of Cluster Headache (2018) (6)
Education and Decision Making at the Time of Triptan Prescribing: Patient Expectations vs Actual Practice (2014) (6)
Subconcussive brain vital signs changes predict head-impact exposure in ice hockey players (2021) (6)
Headache in the elderly (2004) (6)
Mild traumatic brain injury affects the features of migraine (2021) (6)
Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache. (2020) (6)
Amyloidosis presenting with intractable epistaxis and multiple cranial neuropathies. (2000) (6)
Comorbidity in migraine (2011) (6)
Genome-wide screen for stroke: Pilot testing in the Siblings With Ischemic Stroke Study (SWISS) (2000) (6)
A Not So Uncommon Cause of Thunderclap Headache (2002) (6)
Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial (2021) (5)
Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia (2019) (5)
Erratum: Clinical, Anatomical, and Physiologic Relationship between Sleep and Headache (Headache (2003) 43 (282-292)) (2004) (5)
EXTRACEPHALIC CLUSTER (CLUSTER SINE HEADACHE) (2008) (5)
Disability and Economic Loss Caused by Headache among Information Technology Workers in Korea (2021) (5)
Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review (2022) (5)
Mechanisms of thrombogenesis in atrial fi brillation (2009) (5)
The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients (2018) (5)
The emerging role of gammaCore in the management of cluster headache: expert panel recommendations. (2017) (5)
Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial (2021) (5)
Recognizing Sentinel Headache as A Premonitory Symptom in Patients with Aneurysmal Subarachnoid Haemorrhage (2003) (5)
OnabotulinumtoxinA for Treatment of Chronic Migraine: 75% Responder Analysis Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT Clinical Program (P03.227) (2012) (4)
OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phase of the PREEMPT clinical program (2013) (4)
Direct‐to‐Consumer Advertising of OTC Agents Under Current FTC Regulations: Concerns and Comment (2001) (4)
Suboccipital steroid injections for cluster headache (2011) (4)
Diagnosing Secondary and Primary Headache Disorders (2021) (4)
Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary (2021) (4)
Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention (2022) (4)
Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance. (2022) (4)
Triptan Education and Improving Knowledge for Optimal Migraine Treatment: An Observational Study (2014) (4)
OnabotulinumtoxinA for Treatment of Chronic Migraine: A Response (2011) (4)
Introduction: Cardiovascular Safety and Triptans in the Acute Treatment of Migraine (2004) (4)
Ice Hockey Summit II: zero tolerance for head hits and fighting. (2015) (4)
Acute Migraine Therapy (2016) (4)
Developing Common Data Elements (CDEs) for headache clinical research: A National Institute of Neurological Disorders and Stroke (NINDS), NIH initiative (2012) (4)
Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine (2011) (4)
Efficacy of Erenumab for the Treatment of Patients With Chronic Migraine With and Without Aura (S32.006) (2018) (4)
Primary headache associated with sexual activity. (2009) (4)
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain (2022) (4)
Current and emerging treatment options for migraine and other primary headache disorders (2003) (3)
Oxford Textbook of Headache Syndromes (2020) (3)
Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men (2022) (3)
Erenumab Safety Among Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors (P4.100) (2018) (3)
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials (2021) (3)
Proceedings from the Ice Hockey Summit on Concussion: a call to action. (2011) (3)
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine (2020) (3)
75% responder rates provide improvement in HIT-6 scores from week 4 through 12 following a single infusion of ALD403, or placebo. (P2.165) (2017) (3)
Effects of Demographic and Socioeconomic Characteristics on Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the CaMEO (Chronic Migraine Epidemiology & Outcomes) Study (P5.040) (2015) (3)
Site of effect of LY2951742 for migraine prophylaxis–Authors' reply (2015) (3)
Migraine Triggers (2009) (3)
(195) Developing and validating the ID-Chronic Migraine (ID-CM) screening tool (2014) (3)
Non-Pharmacologic Therapy (2016) (3)
OnabotulinumtoxinA for chronic migraine: PREEMPT trials establish a safe and effective dose and injection paradigm (2013) (3)
Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis (2020) (3)
Prolonged Neurologic Complication and MRI Abnormalities Consequent to Intracranial Hypotension (2003) (3)
Facial Pain (2005) (3)
FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine (2022) (3)
Refractory Headaches due to Multilevel Thoracic Cerebrospinal Fluid Leaks (2008) (3)
Sleep restriction alters cortical inhibition in migraine: A transcranial magnetic stimulation study (2022) (3)
Carotid endarterectomy (2000) (3)
Efficacy of Erenumab in Chronic Migraine Patients with Medication Overuse and Prior Preventive Treatment Failure (S38.002) (2019) (3)
Clues from genetic studies. (2008) (3)
Sumatriptan versus eletriptan: which is best? (2002) (3)
Migraine research comes of age in the 21st century (2022) (2)
Proceedings from the Ice Hockey Summit on Concussion: a call to action. (2011) (2)
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults (2022) (2)
Abstract 3196: Effect Of Marital Status On Health-seeking Behavior Following Onset Of Acute Stroke Symptoms (2012) (2)
2017 Migraine in America Symptoms and Treatment (MAST) Study: Gender Differences in Treatment Patterns and Unmet Treatment Needs (P3.145) (2018) (2)
The King-Devick test (KDT) and visual contrast sensitivity test (VCS) in migraine: the effect of migraine attack on rapid eye movements and visual sensitivity (S43.004) (2018) (2)
Epidemiology of diagnosed cluster headache in Norway (2022) (2)
Headache attributed to disorders of homeostasis. (2010) (2)
55-Year-old man with thunderclap headache. (2010) (2)
Prediction of the sphenopalatine ganglion localization in computerized tomography images (2019) (2)
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies (2021) (2)
Migraine and the vascular system: Much has been learned but still a long way to go (2015) (2)
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials (2022) (2)
Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players (2022) (2)
Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks (2023) (2)
Patent foramen ovale closure for migraine prevention: the subject is still open. (2010) (2)
episodic migraine prevention in adults : Report of the Quality Evidence-based guideline update : Pharmacologic treatment for May 15 (2012) (2)
OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT (2013) (2)
HEADACHES AND THEIR RELATIONSHIP TO CEREBROVASCULAR AND CARDIOVASCULAR DISEASE (2006) (2)
Optimal Management of Migraine Taking into Account Comorbidities and ‘Positive Side Effects’ (2011) (2)
Medication‐overuse headache in patients with secondary headache disorders: Need for revision? (2021) (2)
Anatomical landmarks for localizing the otic ganglion: A possible new treatment target for headache disorders (2019) (2)
Perception of the Family Burden of Chronic Migraine: Results of the CaMEO (Chronic Migraine Epidemiology & Outcomes) Study (P5.039) (2015) (2)
The premonitory phase of migraine is due to hypothalamic dysfunction: revisiting the evidence (2022) (2)
Migraine as a Risk Factor for White Matter Lesions, Silent Infarctions, and Ischemic Stroke (2005) (2)
Headache associated with sexual activity: Commentary (2003) (2)
Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine. (2022) (2)
10 Ten Most Commonly Asked Questions About Headaches Associated With Spontaneous Cerebrospinal Fluid Leaks With One Bonus Question! (2002) (2)
The Non‐Inferiority Margins in Migraine Research (NIMM) Survey (2017) (2)
Headache: challenging conventional wisdom (2009) (2)
Post-traumatic Headache: Pharmacologic Management and Targeting CGRP Signaling (2022) (2)
A History of Mild Traumatic Brain Injury Is Associated With a a More Severe Long-term Migraine Phenotype (2021) (2)
White matter hyperintensities in former American football players (2022) (2)
Therapeutic guidelines for headache. (2010) (2)
The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations. (2017) (2)
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle (2022) (1)
Neurogenic inflammation in the pathogenesis of migraine (2002) (1)
Association of ischemic stroke, hormone therapy, and right to left shunt in postmenopausal women (2014) (1)
The Lancet and advertorials (2009) (1)
AUTHOR RESPONSE (2011) (1)
Development of a Responder Definition for the Migraine Physical Function Impact Diary (MPFID) (2016) (1)
Defining the Migraine Phenotype (2012) (1)
Re: Placebo responses in device studies (2018) (1)
Strategies in the Treatment of Migraine–Reply–I (2002) (1)
Migraine comorbidity with cardiac, cardiovascular and cerebrovascular disease (2016) (1)
Neuroimaging in Migraine—Recent Advances and Perspectives for the Future (2010) (1)
Epidemiology and acute care of migraine headache. (2004) (1)
The Percent of Chronic Migraine Patients Who Responded to OnabotulinumtoxinA Treatment Per Treatment Cycle in the PREEMPT Clinical Program (P03.230) (2012) (1)
12 The Medical History: The Key to Correct Headache Diagnosis (2011) (1)
Stroke Telemedicine for Arizona Rural Residents, the Legacy Telestroke Study (2022) (1)
Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212) (2018) (1)
Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache (2022) (1)
Sustained Benefits of OnabotulinumtoxinA Treatment in Chronic Migraine: Results from a PREEMPT Pooled Analysis (1699) (2020) (1)
Effect of CGRP Inhibition with TEV-48125 on Cardiovascular Parameters as a Function of Triptan Use Among Individuals with Chronic Migraine (I3.011) (2016) (1)
Preventing migraine pharmacologically. (2004) (1)
Headache research: A string of pearls (2013) (1)
Prevention of migraine (1969) (1)
How Pain, Including Headache, Becomes Chronic (2007) (1)
The scientific basis of migraine. (2012) (1)
The genetics of common epilepsies: common or distinct? In The Lancet Neurology, the International League Against Epilepsy Consortium on Complex Epilepsies (2014) (1)
The need for continued care after sponsor closure – Authors' reply (2020) (1)
Migrainous infarction of the eye: Two cases of monocular ischemic complications associated with retinal migraine (2021) (1)
Emergency Headache: Diagnosis and Management (2017) (1)
Triptans for Migraine (2012) (1)
Botulinum Toxin Type A (Botox) for Prophylactic Treatment of Chronic Daily Headache: A Response (2006) (1)
Fast Facts: Headaches (2002) (1)
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial (2022) (1)
The impact of pre‐morbid headaches on headache features and long‐term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine Research (2022) (1)
Migraine Symptoms and Diagnosis (2016) (1)
Preclinical Assessment of OnabotulinumtoxinA for the Treatment of Mild Traumatic Brain Injury–Related Acute and Persistent Cephalic Allodynia (2022) (0)
Headache: Cluster headache (2010) (0)
Headache: Introduction to the acute headaches (2010) (0)
Primary and Secondary Red Ear Syndrome: Implications For Treatment: Author's reply (2007) (0)
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies (2022) (0)
Headache: Intracranial neoplasm (2010) (0)
Improvement in Patient-Reported Outcomes When Ubrogepant Is Administered During the Migraine Prodrome (Premonitory Phase): Results From the PRODROME Trial (P9-12.001) (2023) (0)
Headache Currents (2008) (0)
Vision-Based Performance Testing as a Complement to SCAT 3 / Child-SCAT 3 in Youth and Collegiate Athletes (2014) (0)
Headache: Subacute angle-closure glaucoma (2010) (0)
Topical intranasal administration of local anaesthetics over the sphenopalatine foramen: Does this really block the sphenopalatine ganglion? (2017) (0)
Headache: Ischemic stroke (2010) (0)
CT Angiography and Perfusion Studies Do Not Significantly Prolong the Door-to-Needle Times for Acute Stroke Patients Treated with Intravenous Thrombolytics (P02.193) (2012) (0)
Faculty Opinions recommendation of Frontal lobe structure and executive function in migraine patients. (2009) (0)
Treatment of chronic migraine with medication overuse: A perspective (2022) (0)
Board Walk – December 2013 (2013) (0)
IHS: sustaining momentum, fostering collaboration, facilitating advocacy. (2015) (0)
Faculty Opinions recommendation of Association of benign recurrent vertigo and migraine in 208 patients. (2009) (0)
The Time Course of Zolmitriptan Nasal Spray: Rapid Nasal Absorption (2 Minutes), Early CNS Uptake (5 Minutes) and Early Onset of Efficacy (10 Minutes) (2004) (0)
Headache: Sinus headache (2010) (0)
Comprar Migraine 3rd Ed. | David W. Dodick | 9780199793617 | OXFORD (2016) (0)
Response From Friedenberg and Dodick (2001) (0)
Psychometric Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Using Data From Phase 3 Clinical Trials in Patients With Chronic Migraine (CM) and Episodic Migraine (EM) (P8-12.007) (2023) (0)
Response to Letter to the Editor (2015) (0)
Estrogen-dependent abdominal hyperalgesia induced by ovariectomy in adult mice: A model of functional abdominal pain (2007) (0)
Reply - Intractable headache criteria (2007) (0)
Efficacy of Ubrogepant for the Treatment of Migraine Symptoms During the Prodrome (Premonitory Phase): Results From the PRODROME Trial (S47.002) (2023) (0)
Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO) (870) (2020) (0)
Headache: Giant cell arteritis (2010) (0)
The Lancet and advertorials. Authors' reply (2009) (0)
Clinical Uses of Botulinum Toxins: Botulinum toxin type A for the prophylactic treatment of primary headache disorders (2007) (0)
Author response. (2013) (0)
Ubrogepant for the Acute Treatment of Migraine When Administered During the Prodrome (Premonitory Phase): Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled, Crossover Study (S47.001) (2023) (0)
Patient‐reported experiences with migraine‐related cognitive symptoms: Results of the MiCOAS qualitative study (2023) (0)
Cerebral Venous Sinus Thrombosis Masquerading as Cluster Headache (2007) (0)
Characterizing the Patient Experience During the Prodrome Phase of Migraine: A Qualitative Study of Symptoms and Their Timing (P7-12.002) (2023) (0)
EMERGING PREVENTIVE OPTIONS FOR CHRONIC DAILY HEADACHE (2006) (0)
ACGME, TEST THYSELF! (2009) (0)
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data (2023) (0)
Menstrual Migraine: Current Concepts Regarding Pathophysiology, Management, and the Effect of Oral Contraceptive Therapy (1998) (0)
Dr. Dodick replies [13] (2006) (0)
EHMTI-0032. Persistence and switching characteristics among chronic migraine patient population: a retrospective claims analysis (2014) (0)
THE ROLE OF OPIOID THERAPY IN MANAGING CHRONIC DAILY HEADACHE * The following includes a summary of a roundtable discussion with panel members (2002) (0)
Reply to Dr Ravishankar (1998) (0)
Letter from the Editor (2012) (0)
HORMONE REPLACEMENT THERAPY AND RIGHT-TO-LEFT INTRACARDIAC SHUNTS ARE MORE PREVALENT IN POSTMENOPAUSAL WOMEN WITH CRYPTOGENIC STROKE (2012) (0)
Medication Overuse Headache in the Emergency Department (2017) (0)
Headache: Introduction to the chronic daily headaches (2010) (0)
Symptom Bothersomeness in Migraine: Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study (P3.141) (2018) (0)
Migraine Rx in the ED: A Systematic Review (2014) (0)
Less Common Migraine Subtypes (2016) (0)
Headache (1994) (0)
Research Submissions Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial (2007) (0)
The Clinical Characteristics of Migraine (2017) (0)
Headache: Chiari malformation headache (2010) (0)
Editor's Note on Headache Currents (2007) (0)
Letter from the Editor-in-Chief (2015) (0)
Hypnic headache syndrome. Reply to Dr. Ravishankar. (1998) (0)
Letter from the Editor (2009) (0)
Headache: Spontaneous intracranial hypotension (2010) (0)
Canadians publish guidelines for management of migraine (1997) (0)
Epidemiology of Headache in the Emergency Department (2017) (0)
Strategies in the treatment of migraine. Authors' reply (2002) (0)
Headache: Medication-overuse headache (2010) (0)
What's happening in Neurology® Clinical Practice (2019) (0)
Headache: Trigeminal neuralgia (2010) (0)
Total migraine freedom (TMF) for single pulse transcranial magnetic stimulation (sTMS) versus triptans for the early acute treatment of migraine (2013) (0)
Headache: Idiopathic intracranial hypertension (2010) (0)
Headache: Primary stabbing headache (2010) (0)
Can Anything Stop My Migraine (2017) (0)
Patterns of autonomic nervous system impairment following concussion (2013) (0)
Headache: Chronic migraine headache (2010) (0)
Views and Perspectives Defining the Pharmacologically Intractable Headache for Clinical Trials and Clinical Practice (2010) (0)
Headache: SUNCT syndrome (2010) (0)
Journal report from the Editor (2011) (0)
207 OnabotA for CM: benefits beyond headache-day reduction (2022) (0)
Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project (2021) (0)
Chronic migraine and medication overuse headache (2020) (0)
Simultaneous Comparisons of 25 Acute Migraine Medications: A Big Data Analysis of 10 Million Patient Self-Reported Treatment Records From A Migraine Smartphone Application (S41.001) (2023) (0)
MIST: Not the End of the Story (2006) (0)
The Clinical Spectrum of CSF Leaks (2003) (0)
Lack of “wearing off” effect with eptinezumab in the preventive treatment of migraine (P13-12.009) (2023) (0)
ESTRADIOL AND PROGESTERONE DIFFERENTIALLY REGULATE FORMALIN‐INDUCED NOCICEPTION IN OVARIECTOMIZED FEMALE RATS (2007) (0)
Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (S32.005) (2018) (0)
Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project (2021) (0)
Foreword: Triptans for migraine (2012) (0)
Time Tandem Gait (TTG) in Athletes 7–16 Years of Age (2019) (0)
Headache: Intracranial infection (2010) (0)
Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees. (2023) (0)
Headache and neurovascular disorders (2020) (0)
[Episodic to chronic migraine: the basis for the transformation]. (2012) (0)
Patent Foramen Ovale Closure for Migraine Prevention: The Subject Is Still Open⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. (2010) (0)
Developing and Validating the ID-Chronic Migraine (ID-CM) Screening Tool (P5.202) (2014) (0)
Approach to a Challenging Problem Chronic Daily Headache : An Evidence-Based and Systematic (2011) (0)
Factors Associated with Acute Medication Overuse in Persons with Migraine: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study (S43.002) (2018) (0)
Headache: Post-traumatic headache (2010) (0)
Corrigendum (1980) (0)
What's happening in Neurology® Clinical Practice (2019) (0)
Erratum: The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females (Science Translational Medicine DOI: 10.1126/scitranslmed.aay7550) (2020) (0)
Procedural headache medicine in neurology training: a survey of US residency program directors (s19.005) (2015) (0)
A new flortaucipir PET biomarker based on graph theory for early detection of CTE in former American football players (2022) (0)
Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.093) (2018) (0)
Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache (2022) (0)
Neuropsychological test performance of former American football players (2023) (0)
What's happening in Neurology® Clinical Practice (2019) (0)
Headache: Hemiplegic migraine (2010) (0)
Abstract 3818: Reasons To Withhold Anticoagulation In Atrial Fibrillation Subjects After Ischemic Stroke (2012) (0)
Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1st edition (2022) (0)
Headache: Hypnic headache (2010) (0)
Wolff's headache and other head pain : edited by Stephen D. Silberstein, Richard B. Lipton, David W. Dodick (2008) (0)
American Headache adults : Report of the Quality Standards Subcommittee of the complementary treatments for episodic migraine prevention in Evidence-based guideline update : NSAIDs and other April 24 (2012) (0)
FP11-MO-01 Lipid profile and statin use in ischemic stroke and intracerebral hemorrhage (2009) (0)
Comparing Two Ways to Manage Symptoms for Patients Who Have Chronic Migraine and Frequent Medication Use -- The MOTS Trial (2022) (0)
Stroke (2000) (0)
Intractable Headache Criteria: Reply (2007) (0)
Reply to Dr. Merry’s Letter to the Editor (2016) (0)
Faculty Opinions recommendation of Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study. (2008) (0)
Headache: Primary cough headache (2010) (0)
DUPLICATE PUBLICATION (2006) (0)
Headache: New daily persistent headache (2010) (0)
Academic dissertations from the Danish Headache Center 1980–2016 (2017) (0)
Secondary Headache Disordersa (2015) (0)
Migraine and olcegepant – Authors' reply (2009) (0)
A Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase (Plen02.004) (2019) (0)
A Case of Sex Headache and Vasospasm (2004) (0)
Patent Foramen Ovale and Migraine—Where Do We Go From Here? Review of Selected Abstracts and Commentary (2006) (0)
Central Circuits Promoting Chronification of Migraine (2017) (0)
Headache: Pituitary apoplexy (2010) (0)
Headache: Subarachnoid hemorrhage (2010) (0)
Headache: Cervicogenic headache (2010) (0)
Medicolegal Aspects of Headache Medicine Case Studies CASE 1 The Well-Intentioned Triptan Prescriber (2008) (0)
Headache: Primary thunderclap headache (2010) (0)
Stroke: A four-article symposium (2000) (0)
Headache: Chronic tension-type headache (2010) (0)
An evidence-based and experience-based approach to acute migraine treatment (2005) (0)
Identify Chronic Migraine Tool (2016) (0)
Sentinel Headache (2009) (0)
The future of headache classification and classification research (2009) (0)
What's happening in Neurology® Clinical Practice (2019) (0)
Submissions Method of Injection of OnabotulinumtoxinA for Chronic Migraine : A Safe , Well-Tolerated , and Effective Treatment Paradigm Based on the PREEMPT Clinical (2010) (0)
Headache: Occipital neuralgia (2010) (0)
CASE 1: The Well‐Intentioned Triptan Prescriber (2008) (0)
Psychometric Evaluation of the Activity Impairment in Migraine-Diary (AIM-D) Using Data From a Phase 3 (PROGRESS) Clinical Trial in Patients With Chronic Migraine (P8-12.008) (2023) (0)
“Occult” Orthostatic Headache (2002) (0)
Sleep disruption and disorders in former college and professional American football players (2021) (0)
Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis (2022) (0)
Enhanced Pain-Induced Activation of Pain Processing Regions in Interictal Episodic Migraine (S32.004) (2014) (0)
Adv in Ortho and Sport Med : AOASM-107 Proceedings from the Ice Hockey Summit III : Action on Concussion Advances in Orthopaedics and Sports Medicine (2018) (0)
Headache: Basilar-type migraine (2010) (0)
Cephalalgia has flourished over the past 8 years under its publisher, Wiley-Blackwell. (2009) (0)
Exploring the association between migraine and atrial fibrillation utilizing a novel artificial intelligence‐ECG algorithm (2022) (0)
Secondary Headache Disorders (2021) (0)
Exploring the neurobiology of the premonitory phase of migraine preclinically – a role for hypothalamic kappa opioid receptors? (2022) (0)
PL10-FR-01 Migraine (The Richard L. and Mary Masland Lecture) (2009) (0)
Board Walk – September 2017 (2017) (0)
Kappa opioid receptor agonists produce sexually dimorphic and prolactin-dependent hyperalgesic priming. (2022) (0)
Faculty Opinions recommendation of Cough headache: a study of 83 consecutive patients. (2009) (0)
Headache: Colloid cyst of the third ventricle (2010) (0)
In response to: time to re-think the Zurich Guidelines? A critique on the consensus statement on concussion in Sport: the 4th International Conference on Concussion in Sport, held in Zurich, November 2012. (2014) (0)
Third gene identified for hereditary headache (2005) (0)
Taking a headache history (2020) (0)
Headache: Introduction to the episodic headaches (2010) (0)
Identification of Migraine Screener (2020) (0)
White Matter Hyperintensities in Migraine (2017) (0)
Clinical Efficacy and Safety of Ubrogepant for the Acute Treatment of Migraine. (2020) (0)
New research article preparation guidelines (2013) (0)
A 3 item screening instrument had moderate sensitivity and specificity for detecting migraine headaches (2004) (0)
Headache: Acute hypertensive crisis (2010) (0)
The efficiency of the King-Devick Test for detecting concussion in a youth athlete population (2019) (0)
Editorial (2009) (0)
Management of Trigeminal Autonomic Cephalalgias Including Chronic Cluster: A Review. (2023) (0)
Paediatric neurology: advances on many fronts (2009) (0)
3. Cardiovascular Disorders (2011) (0)
Role of Interventional Therapies for Migraine and Headache: Onabotulinum Toxin A, Stimulators, and Nerve Blocks (2019) (0)
Proceedings From the Ice Hockey Summit III: Action on Concussion. (2019) (0)
CHAPTER 60 – OTHER SECONDARY HEADACHE DISORDERS (2007) (0)
2007 Scottsdale Headache Symposium (2008) (0)
CJN volume 31 issue 3 Cover and Front matter (2004) (0)
Cost-Effective Management of Patients with Sinus Headache, Facial Pain, and Pressure: A Decision Analytic Approach (2013) (0)
Early and sustained effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of preempt data (2018) (0)
NOSOLOGICAL ENTITIES ? Thunderclap headache (2001) (0)
The Real-World Impact of OnabotulinumtoxinA on Headache-Related ER Visits and Hospitalizations in the Management of Chronic Migraine (S23.004) (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David William Dodick?

David William Dodick is affiliated with the following schools: